lidocaine 5% / Generic mfg. - LARVOL DELTA

Intralipid® 20% for Reversal of Local Anesthetics (clinicaltrials.gov) - P4 | N=18 | Active, not recruiting | Sponsor: Hospital for Special Surgery, New York | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial primary completion date • Anesthesia

Zoster sine herpete: An atypical presentation of herpes zoster without rash (ASRA-FALL 2025) - "Of note, they were recently diagnosed with pneumonitis concomitant with severe persistent asthma by a pulmonologist and were on week four of a prednisone taper and trimethoprim-sulfamethoxazole regimen...They were also prescribed lidocaine 5% ointment and advised to continue their chronic pain regimen consisting of tapentadol extended-release 50 mg two times daily to provide neuropathic and nociceptive pain control in addition to acetaminophen, celecoxib, 1% diclofenac gel, and cyclobenzaprine...Discussion ZSH is an important diagnosis to consider for immunocompromised patients presenting with acute, localized, dermatomal pain without skin changes or a clear, identifiable source. Similar to HZ, ZSH treatment includes antivirals like valacyclovir or acyclovir alongside analgesics.2,4,5 Prevention also plays an important role with the herpes zoster vaccine given as a two-dose series.1,4 While rare, prompt diagnosis and timely treatment of ZSH are crucial to avoid..."

Asthma • Fibromyalgia • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Neuralgia • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

High dose topical capsaicin in the treatment of meralgia paresthetica: a case report. (PubMed, Pain Manag) - "She had previously tried lidocaine 5% patch, capsaicin 0.1% patch, gabapentin, and oxycodone, with minimal relief. This off-label use of capsaicin 8% patch showed promise for pain management for MP. However, prospective studies are needed to determine the long-term efficacy, safety, and optimal dosing.High-Dose Capsaicin Patch Relieved Thigh Nerve Pain in a Complex Patient - Plain Language Summary."

Journal • Fibrosis • Hematological Disorders • Immunology • Infectious Disease • Neuralgia • Pain • Thrombocytopenia

Trigeminal Neuralgia in the V2 Territory Secondary to Neurovascular Conflict in the Pterygopalatine Fossa: A Case Report (IHC 2025) - "She had been previously diagnosed with trigeminal neuralgia and unsuccessfully treated with carbamazepine...A sequential multimodal treatment was implemented: diagnostic and therapeutic infraorbital nerve blocks (intraoral and extraoral), ganglion sphenopalatine block, topical lidocaine (Versatis®), pregabalin titration, corticosteroids, and botulinum toxin infiltration...Topical anesthetics and neuromodulators (pregabalin and gabapentin) helped reduce intensity and frequency of pain...Conclusion Neurovascular conflict in the pterygopalatine fossa should be considered in cases of refractory trigeminal neuralgia in the V2 territory. High-resolution MRI and a multimodal treatment strategy, including nerve blocks and neuromodulation, can offer significant pain relief and functional recovery in selected cases."

Case report • Clinical • Late-breaking abstract • Migraine

Vulvar Crohn Disease: A Case Report (CDA 2025) - "Management options for VCD may include topical corticosteroids, calcineurin inhibitors, metronidazole , systemic corticosteroids, sulfasalazine , azathioprine, TNFα inhibitors, IL-12/23 inhibitors, and surgical treatment...We continued her adalimumab and prescribed metronidazole 500mg BID. With minimal improvement after 2 months, the patient consented to triamcinolone acetonide 5mg/mL injections (ILTAC) preceded by the application of lidocaine 5% gel...Reports on ILTAC as a treatment modality for VCD are limited in the literature and remain absent from proposed treatment algorithms. Given the considerable improvement our patient experienced with ILTAC injections, it should be considered as a first-line treatment for VCD and for patients who fail other treatment options."

Case report • Clinical • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Inflammatory Bowel Disease • Pain • Pruritus • Psoriasis • IL12A

Airway management in a patient with Zenker's diverticulum and oesophageal foreign body (Euroanaesthesia 2025) - "Awake oral fibreoptic intubation with good tolerance in the OR was performed using nebulization of 4 ml of lidocaine 5% and SAYGO...It is of vital importance to minimize these risks. As there are no specific anaesthesia protocols, anaesthesia and airway management must be individualized to improve each patient's safety."

Clinical • Anesthesia • Gastrointestinal Disorder • Pulmonary Disease

Pharmacological Modulation of Peripheral Nerve Excitability (clinicaltrials.gov) - P=N/A | N=20 | Completed | Sponsor: Aalborg University | Not yet recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Dec 2024

Trial completion • Trial completion date • Pain

Buffered Lidocaine for Topical Nasal Anesthesia: A Double-Blind Randomized Controlled Trial. (PubMed, J Voice) - "Topical nasal anesthesia with plain lidocaine demonstrated a better side effects profile than buffered lidocaine without a significant difference in local anesthesia."

Journal • Anesthesia • Otorhinolaryngology • Pain

Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. (PubMed, Lancet Neurol) - "Our results support a revision of the Neuropathic Pain Special Interest Group recommendations for the treatment of neuropathic pain. Treatment outcomes are modest and for some treatments uncertainty remains. Further large placebo-controlled or sham-controlled trials done over clinically relevant timeframes are needed."

Clinical • Journal • Retrospective data • Review • Addiction (Opioid and Alcohol) • Back Pain • Fibromyalgia • Lumbar Back Pain • Musculoskeletal Pain • Neuralgia • Novel Coronavirus Disease • Pain • Rheumatology

Intralipid® 20% for Reversal of Local Anesthetics (clinicaltrials.gov) - P4 | N=18 | Active, not recruiting | Sponsor: Hospital for Special Surgery, New York | Recruiting ➔ Active, not recruiting

Enrollment closed • Anesthesia

Tips and tricks of anorectal care with topical lidocaine (octose-dan) administration: retrospective, anecdotical, spontaneous, and observational study. (PubMed, Clin Ter) - "No adverse effects of the treatment were recorded. The local symptomatic treatment of haemorrhoids grade one, two, three and of the fissures, and the fistulas with the plain formula: lidocaine 5%; excipient: cetilic acid macrogol, water;( gently administered into and around the anal verge 3-5 minutes before voiding the bowel and reapplied soon after having cleaned and rinsed the anus&perineal area with neutral liquid soap for two months of treatment,) showed highly significant effect (p<0.0001) and highlights the quality of monotherapy on multiple steps of anorectal care."

Journal • Observational data • Retrospective data • Anesthesia • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Pain • Solid Tumor • Thrombosis

Intralipid® 20% for Reversal of Local Anesthetics (clinicaltrials.gov) - P4 | N=18 | Recruiting | Sponsor: Hospital for Special Surgery, New York | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • Anesthesia

Efficacy of Preemptive Topical Lidocaine 5% Plaster in the Prevention of Post-Craniotomy Pain, a Randomized Clinical Trial. (PubMed, J Pain Res) - P3 | "Preemptive lidocaine 5% plaster as a safe technique was not found to be effective in reducing post-craniotomy pain, but potential gender disparities in the outcomes of this method warrant further investigation. ClinicalTrials.Gov (NCT04169854)."

Clinical • Journal • Pain

Retrospective Claims Analysis of Decreased Healthcare Visits and Costs with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch (PAINWeek 2024) - "55,106 patients had LP and 955 had LTS index therapy. From pre- to post-index time periods, average number of office visits, ER visits, and pain procedures (PP) decreased for LTS vs increased for LP (Office: -4% LTS vs 11% LP, p=­­ < 0.01; ER: -12% LTS vs 12% LP; PP: -9% LTS vs 20% LP, p=­ < 0.01). As well, healthcare costs decreased for LTS vs increased for LP for outpatient (-9% LTS vs 8% LP) and ER visits (-5% LTS, 9% LP, p=­ 0.02).Conclusions/Implications for future research and/or clinical care: In these data of neuropathic pain patients, HCRU and associated costs decreased for LTS patients, and increased for LP patients, after starting either therapy."

Retrospective data • Back Pain • CNS Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Multimodal and Interdisciplinary Interventions for the Treatment of Localized Provoked Vulvodynia: A Scoping Review of the Literature from 2010 to 2023. (PAINWeek 2024) - "We identified 27 studies, primarily published in Canada, the US, and Europe. Participants were young, partnered, educated, nulliparous, with 3-7y pain duration. Race, ethnicity and sexual orientation were underreported.Physiotherapy versus Pharmacologic: One RCT produced three publications10-12 comparing topical lidocaine 5% versus weekly physiotherapy."

Review • CNS Disorders • Musculoskeletal Pain • Pain

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (PAINWeek 2024) - "Background: CDC Clinical Practice Guidelines for Prescribing Opioids for Pain recommends maximizing non-opioid pharmacologic therapies and reducing the use of opioids for the treatment of chronic pain1. The final analysis included 6,014 patients taking opioids and either LTS or LP index treatment. 51.9% of LTS patients experienced either a decrease or discontinuation of opioid use in the post-prescription period compared to 45.5% of LP patients (Chi-square test, p=0.021). LTS patients had a non-significant change in pre- versus post-prescription median Morphine Milligram Equivalents (MME) (3.1% increase, Wilcoxon signed rank test, p=0.146); while LP patients experienced a significant increase in pre-versus post-prescription median MME (42.9% increase, Wilcoxon signed rank test, p< 0.001)."

Retrospective data • Back Pain • CNS Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Decreased Cost Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis. (PAINWeek 2024) - "In total, patients treated with LTS demonstrated a reduction in cost while patients treated with LP were associated with an increase in cost in the post-index setting. The median cost of office visits per LTS patient was $2518 pre-index and $2439 post-index (-3%, p=0.003), the median cost of ER/urgent care visits per LTS patient was $1574 pre-index and $1017 post-index (-35%, p=0.663), the median cost of outpatient visits per LTS patient was $2977 pre-index and $2984 post-index (+0.2%, p=0.906 ) and the median cost of pain procedures per LTS patient was $1150 pre-index and $1155 post-index (+0.4%, p=0.107).In contrast, the median cost of office visits per LP patient was $1862 pre-index and $1898 post-index (+2%, p=0.04), the median cost of ER/urgent care visits per LP patient was $2558 pre-index and $2501 post-index (-2%, p=0.624), the median cost of outpatient visits per LP patient was $3636 pre-index and $3926 post-index (+8%, p< 0.001), and the median cost of pain..."

Retrospective data • Back Pain • CNS Disorders • Musculoskeletal Pain • Neuralgia • Pain

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (PAINWeek 2024) - "Sponsored By Scilex This session is not certified for credit. The final analysis included 6,014 patients taking opioids and either LTS or LP index treatment. 51.9% of LTS patients experienced either a decrease or discontinuation of opioid use in the post-prescription period compared to 45.5% of LP patients (Chi-square test, p=0.021). LTS patients had a non-significant change in pre- versus post-prescription median Morphine Milligram Equivalents (MME) (3.1% increase, Wilcoxon signed rank test, p=0.146); while LP patients experienced a significant increase in pre-versus post-prescription median MME (42.9% increase, Wilcoxon signed rank test, p< 0.001)."

Retrospective data • Back Pain • CNS Disorders • Musculoskeletal Pain • Neuralgia • Pain • Peripheral Neuropathic Pain

Decreased Cost Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (PAINWeek 2024) - "In total, patients treated with LTS demonstrated a reduction in cost while patients treated with LP were associated with an increase in cost in the post-index setting. The median cost of office visits per LTS patient was $2518 pre-index and $2439 post-index (-3%, p=0.003), the median cost of ER/urgent care visits per LTS patient was $1574 pre-index and $1017 post-index (-35%, p=0.663), the median cost of outpatient visits per LTS patient was $2977 pre-index and $2984 post-index (+0.2%, p=0.906 ) and the median cost of pain procedures per LTS patient was $1150 pre-index and $1155 post-index (+0.4%, p=0.107).In contrast, the median cost of office visits per LP patient was $1862 pre-index and $1898 post-index (+2%, p=0.04), the median cost of ER/urgent care visits per LP patient was $2558 pre-index and $2501 post-index (-2%, p=0.624), the median cost of outpatient visits per LP patient was $3636 pre-index and $3926 post-index (+8%, p< 0.001), and the median cost of pain..."

Retrospective data • Back Pain • CNS Disorders • Musculoskeletal Pain • Neuralgia • Pain

Efficacy of transdermal lidocaine 5% patches in postoperative analgesia following knee arthroscopy (PubMed, Acta Ortop Mex) - "transdermal lidocaine 5% patches emerge as a promising adjunct to postoperative pain management in knee arthroscopy patients. Their ease of application, minimal side effects, and opioid-sparing effects contribute to a multifaceted analgesic approach. This study underscores the potential of transdermal lidocaine patches in enhancing the overall postoperative experience for knee arthroscopy patients, advocating for their consideration in clinical practice."

Clinical • Journal • Anesthesia • Gynecology • Orthopedics • Pain

Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm in China on May 8, 2024 (PRNewswire) - "Teikoku Pharma USA (TPU) announced today that the NMPA (National Medical Products Administration) has approved Lidoderm ('lidocaine 5% patch as lidocaine cataplasms') for the treatment of Post Herpetic Neuralgia (PHN) in China."

China approval • Neuralgia • Pain

Decreased health care resource utilization with lidocaine topical system 1.8% compared with lidocaine 5% patch: A retrospective claims analysis (AMCP 2024) - No abstract available

HEOR • Retrospective data

Lidocaine patch as noninvasive alternative treatment option in children with anterior cutaneous nerve entrapment syndrome: A retrospective case series. (PubMed, Paediatr Anaesth) - "Lidocaine patches provides pain relief in a substantial portion of children with ACNES."

Journal • Retrospective data • Dermatology • Pain

Pharmacological Modulation of Peripheral Nerve Excitability (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Aalborg University

New trial • Pain

Intralipid® 20% for Reversal of Local Anesthetics (clinicaltrials.gov) - P4 | N=18 | Recruiting | Sponsor: Hospital for Special Surgery, New York | Trial completion date: Jan 2025 ➔ Oct 2025 | Trial primary completion date: Jan 2024 ➔ Oct 2024

Trial completion date • Trial primary completion date • Anesthesia